Sequential intravesical gemcitabine/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy
Kendrick Yim, Kevin Melnick, Sarah L. Mott, Filipe L.F. Carvalho, Affan Zafar, Timothy N. Clinton, Matthew Mossanen, Graeme S. Steele, Michelle S. Hirsch, Natalie M. Rizzo, Chin‐Lee Wu, Kent W. Mouw, Matthew Wszolek, Keyan Salari, Adam S. Feldman, Adam S. Kibel, Michael A. O’Donnell, Mark A. Preston
Topics & Concepts
MedicineBladder cancerCystectomyGemcitabineInternal medicineCystoscopyDocetaxelRetrospective cohort studySalvage therapyCohortSurgeryProportional hazards modelOncologyUrologyUrinary systemCancerChemotherapyBladder and Urothelial Cancer TreatmentsUrinary Bladder and Prostate ResearchImmune responses and vaccinations